Filed by Flex Pharma, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
under the Securities Exchange Act of 1934
Subject Company: Salarius Pharmaceutics, LLC
SEC File No.:
Flex Pharma, Inc. intends to send the following letter to certain of its stockholders beginning on or around May 10, 2019.
May 10, 2019
We have previously sent to you proxy materials for the important Special Meeting of Stockholders of Flex Pharma, Inc., to be held on June 14, 2019.
Your Board of Directors unanimously recommends that shareholders vote FOR the proposals in the proxy materials, which relate to the proposed merger of our wholly owned subsidiary with Salarius Pharmaceuticals, LLC.
One of the conditions to consummating the merger is that Flex Pharmas shareholders approve proposals 1, 2 and 3, as more fully described in the proxy
The affirmative vote of holders of at least a majority of the outstanding shares of Flex Pharmas common stock is required to approve proposals 2 and 3.
Your vote is important
, no matter how many or how few shares you may own.
Please vote TODAY
the Internet, or by
signing, dating and returning the enclosed proxy card in the postage-paid envelope provided.
Very truly yours,
/s/ William McVicar
William McVicar, Ph.D.
President and Chief Executive Officer
You can vote your shares by telephone, or
Please follow the easy instructions on the enclosed proxy card.
If you have any questions, or need assistance in voting
your shares, please call our proxy solicitor,
INNISFREE M&A INCORPORATED,
TOLL-FREE at 1 (888)